- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03536897
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Lynn Shaffer, PhD
- Phone Number: 614-234-3625
- Email: Lynn.Shaffer@mchs.com
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43222
- Recruiting
- Mount Carmel West Hospital
-
Contact:
- Malolan S Rajagopalan, MD
- Phone Number: 614-234-5402
- Email: malolan.rajagopalan@mchs.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female
- ECOG performance status 0-1
- Age 65 years or older
- cT1 or cT2 (≤3.0 cm)
- Invasive ductal carcinoma histology
- Estrogen receptor positive (ER+)
- Grade 1 or Grade 2
- Clinically negative lymph nodes (cN0) by examination, imaging and/or nodal sampling
- Suitable for breast conserving surgery and radiation therapy
- Patient must be able to provide study-specific informed consent
Exclusion Criteria:
- Multi-centric cancer not amenable to single lumpectomy
- Prior ipsilateral whole breast radiation
- Known BRCA 1 or BRCA 2 mutation
- Status post neoadjuvant hormonal or chemotherapy
- Invasive lobular histology
- Pure ductal carcinoma in situ (DCIS)
- Grade 3
- Diffuse suspicious microcalcifications
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
IORT
All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome.
Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered.
Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery.
After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
|
Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-Breast Tumor Recurrence (IBTR)
Time Frame: 5 years
|
Ipsilateral In-Breast Tumor Recurrence (IBTR): defined as biopsy-proved invasive or in situ breast cancer (except LCIS) in the ipsilateral breast.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 5 years
|
Overall Survival
|
5 years
|
Late Toxicity
Time Frame: 5 years
|
Degree of late radiation toxicity will be scored based upon RTOG/EORTC (Radiation Therapy Oncology Group/Eastern Oncology Radiation Therapy Consortium) late radiation morbidity scoring schema for subcutaneous tissue as well as cosmetic result. The RTOG/EORTC late radiation morbidity scoring schema on subcutaneous tissue is as follows:
|
5 years
|
Acute Toxicity
Time Frame: 3 months
|
Acute radiation toxicity will be scored at the first follow-up visit after IORT (4-6 weeks after treatment). Radiation dermatitis will be scored based upon CTCAE (Common Terminology Criteria for Adverse Events) v4.03 scale as follows:
Other acute toxicity will also be scored per the CTCAE v4.03 scale and will be rated on the relation to radiation therapy (definitely related, probably related, possibly related, unlikely related, unrelated) |
3 months
|
Disease Free Survival
Time Frame: 5 yeras
|
Disease Free Survival
|
5 yeras
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malolan Rajagopalan, MD, Mount Carmel Health System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 180212-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on IORT
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
St. Joseph Hospital of OrangeCompletedStage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast CarcinomaUnited States
-
Massachusetts General HospitalIntraOp/MobetronRecruiting
-
Loyola UniversityUnknownPancreas CancerUnited States
-
Benaroya Research InstituteCompletedBreast CancerUnited States
-
University of LouisvilleTerminatedBrain MetastasesUnited States
-
Universitätsmedizin MannheimCompletedNeoplasms | Breast Neoplasms | Breast Diseases | Neoplasm Recurrence, LocalGermany
-
Saint John's Cancer InstituteRecruitingBreast Neoplasms | Early-stage Breast Cancer | Breast Carcinoma in SituUnited States
-
Tianjin First Central HospitalRecruiting